Engineered ecdysone receptor (EcR) (EcR)

The engineered ecdysone receptor (EcR) is a synthetic, ligand-dependent transcription factor that serves as the molecular switch in the RheoSwitch Therapeutic System (RTS) [Karzenowski et al., 2005]. Originally derived from insect species like the spruce budworm (Choristoneura fumiferana), the receptor is modified to be unresponsive to endogenous human hormones, ensuring high specificity and minimal off-target effects in mammalian cells [Palli et al., 2003]. In the presence of a specific small-molecule inducer, such as Veledimex (RG-115932), the engineered EcR undergoes a conformational change that allows it to heterodimerize with a partner protein, usually a chimeric retinoid X receptor (RXR) [Barrett et al., 2018]. This complex then binds to a specific DNA response element to drive the expression of a therapeutic transgene, such as Interleukin-12 (IL-12) [Chiocca et al., 2019]. This technology is primarily utilized in gene therapy and immuno-oncology to provide precise, dose-dependent control over the production of potent therapeutic proteins, allowing clinicians to manage systemic toxicity by modulating the inducer drug dosage [Precigen, 2024].

Other names

RheoSwitch Therapeutic SystemRTSEcdysone-inducible gene switchModified insect ecdysone receptorEcR-based gene switch

The engineered ecdysone receptor (EcR) functions as a ligand-inducible transcription factor within the RheoSwitch Therapeutic System (RTS). Upon binding of a small-molecule inducer (e.g., Veledimex), the engineered EcR forms a heterodimer with a chimeric retinoid X receptor (RXR). This complex then binds to specific DNA response elements (GRE) located upstream of a therapeutic transgene, initiating its transcription and subsequent protein production [Karzenowski et al., 2005; Palli et al., 2003].